Ocugen

Yahoo Finance • 3 days ago

Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and liv... Full story

Yahoo Finance • last month

Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05)Potential 2X treatment benefit compared to 15% and 22% reductions reported for currently approve... Full story

Yahoo Finance • last month

Ocugen to Host Webcast on Tuesday, March 24 at 8 a.m. EDT to Discuss Phase 2 Clinical Trial Data for OCU410—Modifier Gene Therapy for Geographic Atrophy

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and... Full story

Yahoo Finance • 2 months ago

Midday Fly By: IEA to release 400M oil barrels, Oracle reports Q3 beat

The major averages were lower near noon, with the Dow dropping over 400 points as traders weigh shifting oil prices and a key inflation report. Markets are trading cautiously amid volatile energy prices and ongoing geopolitical tensions in... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Wednesday

Major earnings expected before the bell on Wednesday include: * Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]) * Abercrombie & Fitch Co. (ANF [https://seekingalpha.com/symbol/ANF]) * XAI Octagon Floating Rate & Alternative Inc... Full story

Yahoo Finance • 2 months ago

Pre-Market Earnings Report for March 4, 2026 : DY, NXE, BBWI, ANF, WIX, EYE, EYPT, GENI, DAKT, STVN, OCGN, REAX

The following companies are expected to report earnings prior to market open on 03/04/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Dycom Industries, Inc. (DY)is reporting for the quarter ending Janua... Full story

Yahoo Finance • 2 months ago

Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa

Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, reflecting strong interest from investigators and patientsTopline Phase 3 data expected in 1Q 20... Full story

Yahoo Finance • 3 months ago

Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer

MALVERN, Pa., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the appointment of Rita Johnson-Greene as Ch... Full story

Yahoo Finance • 5 months ago

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, CEO, an... Full story

Yahoo Finance • 6 months ago

Ocugen Provides Business Update with Third Quarter 2025 Financial Results

Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA) provided acceptability of a single U.S.-b... Full story

Yahoo Finance • 7 months ago

Ocugen to Present at Industry and Investor Conferences in October 2025

MALVERN, Pa., Oct. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that executive leadership will present a... Full story

Yahoo Finance • 8 months ago

Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Upfront fees and near-term development milestone payments totaling up to $7.5 millionPotential sales milestones of $180 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen to manufacture and supp... Full story

Yahoo Finance • 8 months ago

Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference &amp; Biotech on Tap 2025

MALVERN, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that Dr. Shankar Musunuri, Chairman, Ch... Full story

Yahoo Finance • 9 months ago

Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease

MALVERN, Pa., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Committee for Medicinal Products fo... Full story

Yahoo Finance • 9 months ago

Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced regi... Full story

Yahoo Finance • 9 months ago

Ocugen launches $20 million direct offering of common stock, warrants

* Ocugen (NASDAQ:OCGN [https://seekingalpha.com/symbol/OCGN]) has entered into a securities purchase agreement with Janus Henderson Investors to purchase 20M shares of common stock and warrants for gross proceeds of $20 million * The c... Full story

Yahoo Finance • 9 months ago

Ocugen raises $20 million in registered direct offering

MALVERN, Pa. - Ocugen, Inc. (NASDAQ:OCGN), a biotechnology company focused on gene therapies for blindness diseases, announced today it has secured a $20 million investment through a registered direct offering with Janus Henderson Investor... Full story

Yahoo Finance • 9 months ago

Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purcha... Full story

Yahoo Finance • 9 months ago

MannKind Non-GAAP EPS of $0.05 misses by $0.03, revenue of $76.53M misses by $2.25M

* MannKind press release [https://seekingalpha.com/pr/20190756-mannkind-corporation-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:MNKD [https://seekingalpha.com/symbol/MNKD]): Q2 Non-GAAP EPS of $0.05 misse... Full story

Yahoo Finance • 9 months ago

Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board &amp; Executive Leadership Team

MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Bo... Full story